Tvardi Therapeutics (NASDAQ:TVRD) Rating Increased to Outperform at Raymond James Financial

Raymond James Financial upgraded shares of Tvardi Therapeutics (NASDAQ:TVRD) from a market perform rating to an outperform rating in a research note issued to investors on Wednesday morning, MarketBeat Ratings reports. Raymond James Financial currently has $10.00 target price on the stock.

A number of other research firms have also recently commented on TVRD. HC Wainwright started coverage on shares of Tvardi Therapeutics in a report on Monday, June 8th. They issued a “buy” rating and a $9.00 price target on the stock. BTIG Research restated a “buy” rating and set a $15.00 price objective on shares of Tvardi Therapeutics in a report on Tuesday. UBS Group raised Tvardi Therapeutics to an “outperform” rating and set a $10.00 target price for the company in a research report on Wednesday. Weiss Ratings reissued a “sell (e+)” rating on shares of Tvardi Therapeutics in a research report on Friday, April 10th. Finally, Wall Street Zen lowered Tvardi Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 4th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $24.29.

Tvardi Therapeutics Stock Performance

Shares of NASDAQ TVRD opened at $5.00 on Wednesday. The business’s 50 day moving average price is $3.08 and its 200-day moving average price is $3.53. Tvardi Therapeutics has a fifty-two week low of $1.50 and a fifty-two week high of $43.65. The company has a market cap of $46.90 million, a price-to-earnings ratio of -1.61 and a beta of 0.39.

Tvardi Therapeutics (NASDAQ:TVRD) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.08). Sell-side analysts predict that Tvardi Therapeutics will post -2.39 earnings per share for the current year.

Hedge Funds Weigh In On Tvardi Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Arax Advisory Partners lifted its holdings in shares of Tvardi Therapeutics by 277.2% during the fourth quarter. Arax Advisory Partners now owns 8,400 shares of the company’s stock worth $36,000 after purchasing an additional 6,173 shares during the period. JPMorgan Chase & Co. acquired a new stake in Tvardi Therapeutics during the 2nd quarter valued at approximately $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Tvardi Therapeutics in the 2nd quarter valued at $43,000. HRT Financial LP purchased a new stake in shares of Tvardi Therapeutics in the 4th quarter valued at $47,000. Finally, XTX Topco Ltd acquired a new stake in shares of Tvardi Therapeutics in the fourth quarter worth $55,000. Hedge funds and other institutional investors own 44.66% of the company’s stock.

Key Headlines Impacting Tvardi Therapeutics

Here are the key news stories impacting Tvardi Therapeutics this week:

• Positive Sentiment: Tvardi said Phase 1 results for TTI-109 confirmed the drug’s prodrug design, showed improved tolerability, and demonstrated pharmacodynamic evidence of STAT3 target engagement, including meaningful reductions in disease-relevant immune cell populations. The company also said it plans to advance TTI-109 into STAT3-driven dermatologic and gastrointestinal diseases, subject to additional funding. Article Title
• Positive Sentiment: Piper Sandler upgraded Tvardi Therapeutics from neutral to overweight and set a $13 price target, citing upside potential after the clinical update. Article Title
• Positive Sentiment: Raymond James also upgraded the stock from market perform to outperform with a $10 target, reinforcing investor optimism around the Phase 1 readout. Article Title
• Positive Sentiment: BTIG Research reaffirmed its buy rating and maintained a $15 price target, suggesting analysts see substantial additional upside if development momentum continues. Article Title
• Neutral Sentiment: Trading in TVRD was temporarily halted twice for a LULD pause, reflecting elevated volatility and unusually heavy trading rather than a new fundamental development. Article Title

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.